Evidence map›Paper›PMID 35757299›Full record

ArticleMolecular therapy. Nucleic acids2022

RPS4XL encoded by lnc-Rps4l inhibits hypoxia-induced pyroptosis by binding HSC70 glycosylation site.

Yiying Li, Junting Zhang, Hanliang Sun, Xiufeng Yu, Yujie Chen, Cui Ma, Xiaodong Zheng, Lixin Zhang, Xijuan Zhao, Yuan Jiang and 5 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Roles of LncRNAs in the Pathogenesis of Pulmonary Hypertension.Reviews in cardiovascular medicine · 2024
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Yiying LiBiopharmaceutical Key Laboratory of Heilongjiang Province, College of Pharmacy, Harbin Medical University, Harbin 150081, Heilongjiang Province, P.R. China.
Junting ZhangBiopharmaceutical Key Laboratory of Heilongjiang Province, College of Pharmacy, Harbin Medical University, Harbin 150081, Heilongjiang Province, P.R. China.
Hanliang SunBiopharmaceutical Key Laboratory of Heilongjiang Province, College of Pharmacy, Harbin Medical University, Harbin 150081, Heilongjiang Province, P.R. China.
Xiufeng YuCentral Laboratory of Harbin Medical University (Daqing), Xinyang Road, Gaoxin District, Daqing 163319, P.R. China.
Yujie ChenBiopharmaceutical Key Laboratory of Heilongjiang Province, College of Pharmacy, Harbin Medical University, Harbin 150081, Heilongjiang Province, P.R. China.
Cui MaCentral Laboratory of Harbin Medical University (Daqing), Xinyang Road, Gaoxin District, Daqing 163319, P.R. China.
Xiaodong ZhengDepartment of Genetic And Cell Biology, Harbin Medical University (Daqing), Daqing 163319, P. R. China.
Lixin ZhangCollege of Medical Laboratory Science and Technology, Harbin Medical University, Daqing, Heilongjiang Province, China.
Xijuan ZhaoCentral Laboratory of Harbin Medical University (Daqing), Xinyang Road, Gaoxin District, Daqing 163319, P.R. China.
Yuan JiangBiopharmaceutical Key Laboratory of Heilongjiang Province, College of Pharmacy, Harbin Medical University, Harbin 150081, Heilongjiang Province, P.R. China.
Wei XinBiopharmaceutical Key Laboratory of Heilongjiang Province, College of Pharmacy, Harbin Medical University, Harbin 150081, Heilongjiang Province, P.R. China.
Shanshan WangBiopharmaceutical Key Laboratory of Heilongjiang Province, College of Pharmacy, Harbin Medical University, Harbin 150081, Heilongjiang Province, P.R. China.
Jiye HuCollege of Medical Laboratory Science and Technology, Harbin Medical University, Daqing, Heilongjiang Province, China.
Mingge WangHarbin Medical University, Harbin 150081, Heilongjiang Province, P.R. China.
Daling ZhuBiopharmaceutical Key Laboratory of Heilongjiang Province, College of Pharmacy, Harbin Medical University, Harbin 150081, Heilongjiang Province, P.R. China.
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pyroptosis is involved in pulmonary hypertension (PH); however, whether this process is regulated by long non-coding RNAs (lncRNAs) is unclear. Some lncRNAs encode peptides; therefore, whether the regulation of pyroptosis in PH depends on lncRNAs themselves or their encoded peptides needs to be explored. We aimed to characterize the role of the peptide RPS4XL encoded by lnc-Rps4l and its regulatory mechanisms during pyroptosis in PH. Transgenic mice overexpression of lnc-Rps4l was established to rescue the inhibition of hypoxia-induced pyroptosis in pulmonary artery smooth muscle cells (PASMCs). An adeno-associated virus 9 construct with a mutation in the open reading frame of lnc-Rps4l was used to verify that it could inhibit hypoxia-induced PASMCs pyroptosis through its encoded peptide RPS4XL. Glutathione S-transferase (GST) pull-down assays revealed that RPS4XL bound to HSC70, and microscale thermophoresis (MST) was performed to determine the HSC70 domain that interacted with RPS4XL. Through glycosylation site mutation, we confirmed that RPS4XL inhibited hypoxia-induced PASMCs pyroptosis by regulating HSC70 glycosylation. Our results showed that RPS4XL inhibits pyroptosis in a PH mouse model and hypoxic PASMCs by regulating HSC70 glycosylation. These results further clarify the important mechanism of vascular remodeling in PH pathology.

Indexed as

HSC70hypoxialnc-Rps4lMT: Non-coding RNAspulmonary arterial hypertensionpyroptosisRPS4XL

Identifiers

PMID35757299
PMCPMC9185019
OpenAlexW4281249570

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.